skip to content

Investors

Roche Full Year Results 2025

Thursday, 29 January 2026 at 13:30 CET

More details

A blue-gloved hand delicately holds a small pink container with a QR code. Nearby are green, blue, and yellow containers on a white surface, indicating a scientific setting.

Roche’s Virtual Oncology/SABCS Investor Event

Roche has hosted a virtual event on Thursday, 11 December 2025

Please click here to watch the replay
Presentation download

A gloved hand in a lab coat holds a small, clear vial against a blurred background of lab equipment, conveying a scientific and clinical setting.

24 million

patients were treated with Roche medicines in 2024

30 billion

Roche Diagnostics test were delivered to customers worldwide in 2024

+1%

Core investments in research and development in 2024: CHF 13.2 billion

Our two divisions are focusing jointly on three disease areas that will account for almost 50% of the global disease burden by 2035: cancer, cardiovascular-metabolic diseases and neurological diseases.

Portrait of Thomas Schinecker

Dr Thomas Schinecker

CEO Roche Group

Upcoming Investor events

View all events

J.P. Morgan 2026 Healthcare ConferenceInvestors

January 12, 2026 at 10:00 PST | San Francisco, US

Octavian Seminar 2026Investors

January 15, 2026 at 10:00 CET | Davos, CH

Roche Full Year Results 2025 (virtual event)Investors

January 29, 2026 at 13:30 CET | Basel, Switzerland

TD Cowen 4th Annual Healthcare ConferenceInvestors

March 03, 2026 at 08:00 EST | Boston, UK

UBS European Healthcare ConferenceInvestors

March 03, 2026 at 08:00 GMT | London, UK

Barclays Global Healthcare ConferenceInvestors

March 10, 2026 at 08:00 GMT | Miami, US

2026 Annual General Meeting (tentative)Investors

March 10, 2026 at 10:30 CET | Basel, Switzerland

BNP Paribas Exane Healthcare ConferenceInvestors

March 24, 2026 at 08:00 GMT | London, UK

Goldman Sachs Biopharma Innovation SummitInvestors

March 25, 2026 at 08:00 GMT | London, UK

Investor relations team contacts

Do you need to get in touch with us? Reach out to our investor relations team with your enquiries.